Table 4.

Association between lifetime duration of hormone therapy use and endometrial cancer, by delay between menopause and start of hormone therapy.

	Menopause–Hormone Therapy Delay
	< 1 year		≥ 1 year
HT Category	N Ca (Co)	OR (95%CI)* per 5-year use	N Ca(Co)	OR (95%CI)* per 5-year use	P for Interaction
Never Use	100 (223)	1 (Ref)	100 (223)	1 (Ref)
ET/Short-Sequential EPT	83 (103)	1.63 (1.38–1.95)	42 (40)	2.00 (1.46–2.79)	0.259
Continuous-Combined EPT	76 (136)	1.35 (1.16–1.58)	42 (87)	1.16 (0.93–1.44)	0.151
ET/Short-Sequential EPT (only)	53 (61)	1.85 (1.50–2.32)	26 (31)	1.86 (1.35–2.65)	0.472
Continuous-Combined EPT (only)	49 (91)	1.37 (1.16–1.63)	28 (76)	1.08 (0.82–1.38)	0.076

^*Mutually adjusted ORs per 5 year of use; adjusted for age, race, reference year, geographic area of residence, menopause age, number of full-term pregnancies, age at the last full-term pregnancy, lifetime oral contraceptive use duration and body mass index

Abbreviations: ET: Estrogen Therapy; EPT: Estrogen-Progestin Therapy; OR: Odds Ratio; CI: Confidence Interval; Ca: Case; Co: Control; Ref: Reference Group; HT: Hormone Therapy